Background: Quetiapine, an atypical antipsychotic endowed with weak dopamine
antagonist, potent 5-HT2A-blocking, partial 5-HT1A-agonist, anti-H1 histamine, adrenolytic …

Purpose The antipsychotic agent quetiapine was introduced in Norway in 2003. We have
assessed changes in dispensed prescriptions, including dosing, of quetiapine in Norway …

Recent years have seen a significant increase in the reports of atypical antipsychotic
diversion, misuse and even dependency syndrome. These reports have arisen amidst a …

Introduction Second-generation antipsychotics (SGA) are associated with misuse potential;
however, there are limited data describing the prevalence and characteristics of this misuse …

The first case describing the deliberate M/A of an anticholinergic medication for its euphoric
effects was published in 1960. Further reports followed in Europe before the M/A potential of …

In 1998 the Australian Government Department of Health and Ageing (AGDHA)
commissioned the National Drug and Alcohol Research Centre (NDARC) to implement a …

Abstract Background and Aims There are ongoing concerns regarding the extra-medical use
of quetiapine and related harms. We aimed to investigate trends in quetiapine use and extra …

In 1998 the Australian Government Department of Health and Ageing (AGDHA)
commissioned the National Drug and Alcohol Research Centre (NDARC) to implement a …

Amaç: Bağımlılık potansiyelleri nedeniyle terapötik amaçlar için kullanılan psikoaktif ilaçların
kötüye kullanımı günden güne yaygınlaşmaktadır. Birçok çalışmada, ketiapinin yasadışı …

Objective: Abuse of psychoactive drugs for therapeutic purposes is becoming more common
due to their addiction potential. In many studies, quetiapine has been reported to be abused …